A5085375744- Cancer Immunotherapy and Biomarkers
- Monoclonal and Polyclonal Antibodies Research
- Breast Cancer Treatment Studies
- Biosimilars and Bioanalytical Methods
- Advanced Breast Cancer Therapies
- Pharmaceutical studies and practices
- Lung Cancer Treatments and Mutations
- Colorectal Cancer Treatments and Studies
- Esophageal Cancer Research and Treatment
- Economic and Financial Impacts of Cancer
- Immunodeficiency and Autoimmune Disorders
- Cannabis and Cannabinoid Research
- Cancer Diagnosis and Treatment
- Gastroesophageal reflux and treatments
- T-cell and B-cell Immunology
- Gastric Cancer Management and Outcomes
- Psoriasis: Treatment and Pathogenesis
- Pancreatic and Hepatic Oncology Research
- Tryptophan and brain disorders
- Tuberculosis Research and Epidemiology
- Neutropenia and Cancer Infections
- Radiomics and Machine Learning in Medical Imaging
- Brain Metastases and Treatment
- Lung Cancer Diagnosis and Treatment
- Gallbladder and Bile Duct Disorders
Second Affiliated Hospital of Nanchang University
2024
Nanchang University
2024
Merck & Co., Inc., Rahway, NJ, USA (United States)
2021-2023
Amgen (United States)
2014
Abbott Fund
2001
AMG 139 is a human anti-IL-23 antibody currently in phase II trial for treating Crohn's disease. To support its clinical development humans, vitro assays and vivo studies were conducted cynomolgus monkeys to determine the pharmacology, preclinical characteristics safety of this monoclonal antibody.
The interaction between cocaine (COC) and ethyl alcohol (ALC) was investigated in ALC-naive ALC-pretreated rats. In each group, COC (30 mg/kg ip) administered 15 min after administration of ALC (3 g/kg, by gavage) or normal saline (NS), a balanced cross-over experimental design. Cocaethylene (CE) detected only the rat plasma when with COC. rats, area under concentration-time curve (AUC) maximum concentration (Cpmax) were significantly higher COC+ALC compared COC+NS. However, half-life (t1/2)...
To compare the efficacy of Three-scope combined (laparoscopic, rigid choledochoscopy and electronic choledochoscopy, TS) with laparoscopic hepatectomy (LH) for patients hepatolithiasis (HL). Between January 2019 2020, 118 consecutive HL treated TS (TS group, n = 57) or LH (LH 61) were analyzed in this study. Perioperative long-term outcomes, including operative time, intraoperative blood loss, transfusion, postoperative bowel function recovery hospital stay, complication rate, stone removal...
Aim: To compare the 24‐h intragastric pH effects of simplified lansoprazole suspension, 30 mg, administered nasogastrically, with pantoprazole, 40 intravenously. Methods: Thirty‐six healthy adults were enrolled and given mg (nasogastrically), or (intravenously), once daily for five consecutive days in a cross‐over fashion. Intragastric was monitored at baseline on Days 1 5 each treatment period. The pharmacokinetic parameters pantoprazole also determined 5. Results: No statistically...
P008 Pharmacokinetics and pharmacodynamics in cynomolgus monkeys of AMG 181, a fully human anti a4 b7 antibody for treating inflammatory bowel disease W.-J. Pan1 *, S. Lear2, Patel1, P. Prince1, D. Doherty1, C.-Y. Tam1, C. Sheckler1, H. Hsu3, W. Rees2, A. Anderson4, J. Wisler5, K. Reynhardt6, Lynch7, Brandvig8, L. Wienkers1, Borie9. 1Amgen Inc., Drug Metabolism, Seattle, United States, 2Amgen Molecular Sciences Computational Biology, 3Amgen Inflammation, Thousand Oaks, 4Amgen 5Amgen...
P225 Pharmacokinetics/pharmacodynamics and safety of AMG 181, a fully human anti-a 4 b 7 antibody for treating inflammatory bowel diseases (IBD) W.-J. Pan1 *, B. Sullivan2, C. Evangelista2, D. Doherty1, C.-Y. Tam1, S. Patel1, P. Prince1, K. Reynhardt3, W. Rees4, H. Hsu5, Zhou6, Gu7, M. Yen8, Haller9, Dodson10, Z. Yu10, L. Wienkers1, Borie11. 1Amgen Inc., Pharmacokinetics Drug Metabolism, Seattle, United States, 2Amgen Clinical Immunology, Thousand Oaks, 3Amgen 4Amgen Molecular Sciences...
P008 Pharmacokinetics and pharmacodynamics in cynomolgus monkeys of AMG 181, a fully human anti a4 b7 antibody for treating inflammatory bowel disease W.-J. Pan1 *, S. Lear2, Patel1, P. Prince1, D. Doherty1, C.-Y. Tam1, C. Sheckler1, H. Hsu3, W. Rees2, A. Anderson4, J. Wisler5, K. Reynhardt6, Lynch7, Brandvig8, L. Wienkers1, Borie9. 1Amgen Inc., Drug Metabolism, Seattle, United States, 2Amgen Molecular Sciences Computational Biology, 3Amgen Inflammation, Thousand Oaks, 4Amgen 5Amgen...